Searchable abstracts of presentations at key conferences in endocrinology

ea0086op6.4 | Endocrine Cancer and Late Effects | SFEBES2022

Endocrinopathies in cancer patients receiving immune checkpoint inhibitors are associated with an improved overall survival

Murthy Sruthi , Mahmoud Sarah , Gonzalez Michael A , Martin Niamh M

Background: Immune checkpoint inhibitors (ICIs) including programmed-death cell-1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) re-activate T lymphocytes and promote cancer cell death. Immune-related adverse events (irAEs) are common in cancer patients receiving ICIs. Endocrine irAEs include primary thyroid dysfunction, hypophysitis, type 1 diabetes mellitus (T1DM) and primary adrenal insufficiency. These endocrinopathies may require a...

ea0038p316 | Pituitary | SFEBES2015

Does basal post-operative early morning cortisol measurement predict HPA axis integrity as assessed by an insulin tolerance test in patients who have undergone pituitary surgery?

Ahmad Syed Mustafa Ali , Papadopoulou Debbie , Hatfield Emma , Mendoza Nigel , Nair Ramesh , Meeran Karim , Martin Niamh M

Background: Correct identification of patients with HPA axis dysfunction following trans-sphenoidal pituitary surgery is important. Our centre measures post-operative day 5 0900 h serum cortisol (24 h after the last dose of glucocorticoid) to identify the need for glucocorticoid replacement. This is given if post-operative day 5 0900 h cortisol concentration is <300 nmol/l, until dynamic pituitary function assessment occurs.Methods: Data were reviewe...

ea0031p159 | Neoplasia, cancer and late effects | SFEBES2013

The relationship between anatomical location of phaeochromocytoma and paraganglioma and their secretory properties

Lim Chung Thong , Gill Jasdeep , Ramachandran Radha , Brook Susan E , Martin Niamh M , Dhillo Waljit , Todd Jeannie , Palazzo Fausto , Caplin Martyn , Bouloux Pierre , Meeran Karim , Tan Tricia , Khoo Bernard

Background: Phaeochromocytomas (PCC) and paragangliomas (PGL) are neuroendocrine tumours that can secrete catecholamines. PCC are found in the adrenals, whereas PGL are found at any level between the skull base to the pelvis. More than 25% of cases are associated with mutations in susceptibility genes such as the SDH subunits. Screening for PCC/PGL crucially depends on detection of biochemical markers such as catecholamines and metanephrines (catecholamine metabolites).<p ...

ea0063oc3.2 | Cushing's and acromegaly | ECE2019

Outcomes after primary treatment for Nelson’s syndrome: a study from 13 UK centres

Fountas Athanasios , Lim Eugenie , Drake William M , Polson Andrew , Gurnell Mark , Martin Niamh M , Seejore Khyatisha , Murray Robert D , MacFarlane James , Ahluwalia Rupa , Swords Francesca , Ashraf Muhammad , Pal Aparna , Chong Zhuomin , Freel Marie , Balafshan Tala , Purewal Tejpal S , Speak Rowena G , Newell-Price John , Higham Claire , Hussein Ziad , Baldeweg Stephanie E , Dales Jolyon , Reddy Narendra , Levy Miles , Karavitaki Niki

Nelson’s syndrome (NS) is a potentially severe complication following bilateral adrenalectomy for Cushing’s disease (CD). Series assessing outcomes of treatments for NS are limited by small sample size, often short follow-up and variability of success criteria. We performed a UK multi-centre study aiming to review outcomes of primary treatment for NS. Clinical, laboratory, imaging data were collected. Kaplan-Meier method, log-rank test, Cox regression analysis were u...